Ulisse Biomed Valuation
Is UBM undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of UBM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate UBM's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate UBM's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for UBM?
Key metric: As UBM is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is UBM's PS Ratio? | |
|---|---|
| PS Ratio | 42.6x |
| Sales | €420.92k |
| Market Cap | €17.93m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 40.7x |
| Enterprise Value/EBITDA | -2.7x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does UBM's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 9.1x | ||
ARBS Arterra Bioscience | 3.5x | n/a | €12.6m |
ONC Oncimmune Holdings | 14.1x | 105.1% | UK£17.2m |
A352770 Clinomics | 2.2x | n/a | ₩21.4b |
CYP Cynata Therapeutics | 16.8x | 70.4% | AU$38.8m |
UBM Ulisse Biomed | 42.6x | 46.1% | €17.9m |
Price-To-Sales vs Peers: UBM is expensive based on its Price-To-Sales Ratio (42.6x) compared to the peer average (9.1x).
Price to Sales Ratio vs Industry
How does UBM's PS Ratio compare vs other companies in the European Biotechs Industry?
| 38 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 38 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: UBM is expensive based on its Price-To-Sales Ratio (42.6x) compared to the European Biotechs industry average (7.9x).
Price to Sales Ratio vs Fair Ratio
What is UBM's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 42.6x |
| Fair PS Ratio | 0.2x |
Price-To-Sales vs Fair Ratio: UBM is expensive based on its Price-To-Sales Ratio (42.6x) compared to the estimated Fair Price-To-Sales Ratio (0.2x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.